Cochlear is the world's largest manufacturer of cochlear implants, devices that restore hearing for people with severe to profound hearing loss by directly stimulating the auditory nerve, bypassing damaged parts of the ear that conventional hearing aids cannot help. The company's FY26 results showed …
Cynata's core technology is its CymerusManufacturingplatform, which produces mesenchymal stem cells from induced pluripotent stem cells rather than from individual donor tissue. The company has positioned this as a scalable alternative to conventional donor-derived cell therapy manufacturing, since a single starting cell line can …
ImpediMed's core technology, SOZO, uses bioimpedance spectroscopy to measure fluid status in the body, with its primary clinical application in detecting and monitoring lymphoedema — a chronic swelling condition that commonly affects cancer survivors following lymph node removal or radiation therapy. Early detection of …
Tissue Repair is a clinical-stage biopharmaceutical company developing advanced wound-healing products built around its Glucoprime technology, a proprietary beta-glucan molecule extracted from yeast that is designed to activate macrophages and stimulate the immune response involved in tissue repair and skin regeneration. Its lead candidate, …
CannEpil is a standardised 20:1 cannabidiol-to-tetrahydrocannabinol oral solution developed for drug-resistant epilepsy. In July 2026, Argent announced a global licensing framework with US$5.5 million of upfront consideration structured as forgiveness of approximately US$5.5 million of Mercer Street convertible debt. The company said completion would …
Shareholders approved the name change from Opthea to Ceryvyn Therapeutics in July 2026, and theASX Codechanged from OPT to CYV. The company shifted its development focus from ophthalmology to a programme targeting lymphangioleiomyomatosis (LAM). Its corporate contact details and service arrangements do not by …
Eftilagimod alfa, known as efti, is Immutep's lead product candidate, a soluble LAG-3 fusion protein designed to activate antigen-presenting cells and broadly stimulate the immune system's response against tumours. Unlike checkpoint inhibitors that block a single suppressive signal, efti is designed to work upstream, …
Azer-cel is an allogeneic, or off-the-shelf, CD19-directed CAR T-cell therapy being developed for patients with relapsed or refractory diffuse large B-cell lymphoma, and it incorporates interleukin-2 to help support T-cell persistence and activity. Unlike autologous CAR-T therapies manufactured individually from each patient's own cells, …
EmtinB is a therapeutic peptide that NeuroScientific investigated for possible use in neurodegenerative conditions. The company later said it decided in 2023 to focus EmtinB development on ophthalmology, with local delivery into the eye under evaluation for advanced glaucoma. Preclinical requirements and any future …
Global Health has provided healthcare software since 1993. Its platforms connect clinicians, care teams and consumers, including provider systems and the Lifecard personal health record.